Report error Found 580 Enz. Inhib. hit(s) with all data for entry = 1513
Affinity DataIC50: 2.19nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.19nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.43nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.48nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.57nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.64nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.68nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.70nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.77nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.86nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.92nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 2.99nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.05nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.07nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.24nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.28nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.35nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.49nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.61nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.67nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.77nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.80nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.82nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.84nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.86nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.87nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.92nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.93nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.94nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.96nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 3.99nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.01nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.09nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.14nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.16nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.18nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.25nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.27nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.35nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.35nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.36nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.36nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.38nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.38nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.38nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.38nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.47nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.51nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.59nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
Affinity DataIC50: 4.59nMAssay Description:The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., a biochemical TR-FRET assay....More data for this Ligand-Target Pair
